Table 2 Baseline characteristics of T2DM patients with and without overweight
From: Impact of overweight on left ventricular function in type 2 diabetes mellitus
|  | T2DM patients with overweight (n = 70) | T2DM patients without overweight (n = 75) | p value |
|---|---|---|---|
Clinical data | |||
 Age, years | 59 ± 14 | 61 ± 13 | 0.31 |
 Female, n (%) | 36 (51) | 31 (41) | 0.22 |
 Body mass index, kg/m2 | 30 ± 4 | 22 ± 2 | < 0.05 |
 Heart rate, bpm | 72 ± 13 | 70 ± 11 | 0.25 |
 DM duration, years | 12 ± 8 | 10 ± 10 | 0.31 |
 Hypertension, n (%) | 46 (66) | 39 (53) | 0.11 |
 Dyslipidemia, n (%) | 55 (79) | 35 (47) | < 0.05 |
Blood exam and urinary test | |||
 HbA1c, % | 8.5 ± 1.6 | 8.7 ± 2.5 | 0.53 |
 Low-density lipoprotein, mg/dL | 107 ± 31 | 110 ± 37 | 0.52 |
 Triglyceride, mg/dl | 165 ± 75 | 138 ± 89 | < 0.05 |
 eGFR, mL/min/1.73 m2 | 72 ± 24 | 77 ± 26 | 0.24 |
Medical treatment | |||
 CCB, n (%) | 33 (47) | 15 (20) | < 0.05 |
 ACEI/ARB, n (%) | 41 (59) | 30 (41) | < 0.05 |
 β-Blocker, n (%) | 7 (10) | 6 (8) | 0.78 |
 Statin, n (%) | 44 (63) | 25 (34) | < 0.05 |
 Insulin, n (%) | 41 (59) | 32 (43) | 0.07 |
 DPP-4I, n (%) | 38 (54) | 39 (53) | 0.85 |
 GLP-1RA, n (%) | 12 (17) | 2 (2) | < 0.05 |
 Sulfonylurea, n (%) | 18 (26) | 18 (24) | 0.84 |
 α-GI, n (%) | 12 (17) | 17 (23) | 0.36 |
 Thiazolidine, n (%) | 10 (14) | 4 (5) | 0.09 |
 Metformin, n (%) | 44 (63) | 35 (47) | 0.06 |
Echocardiography | |||
 LV end systolic volume, mL | 28 ± 10 | 25 ± 10 | 0.08 |
 LV end diastolic volume, mL | 78 ± 21 | 72 ± 21 | 0.13 |
 LV ejection fraction, % | 65 ± 5 | 66 ± 4 | 0.06 |
 Stroke volume, mL | 64 ± 14 | 62 ± 11 | 0.34 |
 Left atrial volume index, mL/m2 | 31 ± 9 | 29 ± 8 | 0.08 |
 LV mass index, g/m2 | 84 ± 19 | 75 ± 21 | < 0.05 |
 E/e′ | 11.1 ± 4.0 | 10.3 ± 4.1 | 0.26 |
 e′ | 5.8 ± 1.4 | 6.3 ± 1.8 | 0.06 |
 Global longitudinal strain, % | 17.0 ± 2.4 | 18.9 ± 2.6 | < 0.05 |